tradingkey.logo

Werewolf Therapeutics Receives Fast Track Designation From The U.S. FDA For WTX-124, An Investigational Therapy For The Treatment Of Cancer

ReutersOct 8, 2025 12:08 PM

- Werewolf Therapeutics Inc HOWL.O:

  • WEREWOLF THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM THE U.S. FDA FOR WTX-124, AN INVESTIGATIONAL THERAPY FOR THE TREATMENT OF CANCER

  • WEREWOLF THERAPEUTICS INC: ANTICIPATE SHARING PRELIMINARY DATA FROM ONGOING WTX-124 PHASE 1/1B CLINICAL TRIAL IN Q4

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI